A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

03 Jun 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Background. Rituximab (RTX) represents an established therapeutic option for myasthenia gravis refractory to conventional immunotherapy. However, its heterogeneous efficacy across populations creates a challenge in clinical application, necessitating the development of robust predictive models to better identify patients likely to derive meaningful benefit from this treatment. Methods.
This study retrospectively reviewed the patients who visited the research center and received RTX treatment between August 2019 and January 2025. The primary outcome measure was minimal symptom expression (MSE). A predictive model was constructed using logistic regression and presented in a nomogram. The performance of the model was evaluated by calculating the area under the receiver operating characteristic curve (AUC), with internal validation performed via the bootstrap method.
The study population was divided into high- and low- probability groups according to Youden index. Calibration curves with 1000 replications bootstrap resampling were plotted to visualize the calibration of the nomogram. Decision curve analyzes (DCA) with 1000 replications bootstrap resampling were per formed to evaluate the clinical usefulness of the model. Results.
A total of 117 patients were included.

Clinical Editorial

Summary

Frontiers in Immunology published a clinical update in Infectious Disease on 03 Jun 2026.

The item focuses on A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation.

Review the original article for the full source wording and details.